下肢18F-NaF PET/CT逐血管分析可量化外周动脉疾病患者中糖尿病和慢性肾病诱导的活跃微钙化
本研究对48例外周动脉疾病(PAD)患者和8例健康对照行下肢18F-NaF PET/CT,逐血管量化活跃微钙化。合并糖尿病(DM)或慢性肾病(CKD)的PAD患者所有目标动脉的18F-NaF摄取均显著高于无DM或CKD者,且校正年龄、性别和体质指数后仍显著。他汀使用仅与股腘动脉微钙化降低相关,CT可检测钙化与18F-NaF摄取在5条动脉中的4条无显著关联。
要点
- 合并DM或CKD的PAD患者所有下肢目标动脉18F-NaF摄取均显著高于无DM或CKD的PAD患者。
- 他汀使用仅与股腘动脉微钙化降低相关,其余动脉未见显著关联。
- CT可检测钙化与18F-NaF摄取在5条目标动脉中的4条无显著关联。
核心结论
- 18F-NaF PET/CT可量化PAD患者血管特异性活跃微钙化,DM和CKD使多条下肢动脉微钙化增加,他汀使用使股腘动脉微钙化降低。
- 18F-NaF PET显像与CT可检测动脉钙化互补且 largely 独立。
- 18F-NaF PET/CT可能为无创量化PAD患者对新兴抗动脉粥样硬化治疗或CKD治疗血管特异性反应提供方法。
研究设计与样本
- PAD患者(n=48)和健康对照(n=8)接受下肢18F-NaF PET/CT显像。
- 融合PET/CT图像引导目标动脉(股腘动脉、胫前动脉、胫腓干、胫后动脉和腓动脉)分割及18F-NaF摄取量化。
- 逐动脉评估18F-NaF摄取并在受试组间比较,同时用CT钙质量评分量化各动脉已形成钙负荷。
- 采用单因素和多因素分析评估DM、CKD、他汀使用和CT钙质量作为PAD中18F-NaF摄取的预测因素。
主要发现
- 合并DM或CKD的PAD患者所有动脉的活跃微钙化(即18F-NaF摄取)显著高于无DM或CKD的PAD患者。
- 单因素和多因素分析显示,合并DM或CKD与所有目标动脉微钙化增加相关,校正年龄、性别和体质指数后该疾病风险增加仍显著。
- 多因素分析中,他汀使用仅与股腘动脉微钙化降低相关。
- CT可检测钙化与18F-NaF摄取在5条目标动脉中的4条无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Positron emission tomography (PET)/computed tomography (CT) imaging with fluorine-18 (18F)-sodium fluoride (NaF) provides assessment of active vascular microcalcification, but its utility for evaluating diabetes mellitus (DM)- and chronic kidney disease (CKD)-induced atherosclerosis in peripheral arterial disease (PAD) has not been comprehensively evaluated. This study sought to use 18F-NaF PET/CT to quantify and compare active microcalcification on an artery-by-artery basis in healthy subjects, PAD patients with or without DM, and PAD patients with or without CKD. Additionally, we evaluated the contributions of DM, CKD, statin use and established CT-detectable calcium to 18F-NaF uptake for each lower extremity artery. METHODS: PAD patients (n = 48) and healthy controls (n = 8) underwent lower extremity 18F-NaF PET/CT imaging. Fused PET/CT images guided segmentation of arteries of interest (i.e., femoral-popliteal, anterior tibial, tibioperoneal trunk, posterior tibial, and peroneal) and quantification of 18F-NaF uptake. 18F-NaF uptake was assessed for each artery and compared between subject groups. Additionally, established calcium burden was quantified for each artery using CT calcium mass score. Univariate and multivariate analyses were performed to evaluate DM, CKD, statin use, and CT calcium mass as predictors of 18F-NaF uptake in PAD. RESULTS: PAD patients with DM or CKD demonstrated significantly higher active microcalcification (i.e., 18F-NaF uptake) for all arteries when compared to PAD patients without DM or CKD. Univariate and multivariate analyses revealed that concomitant DM or CKD was associated with increased microcalcification for all arteries of interest and this increased disease risk remained significant after adjusting for patient age, sex, and body mass index. Statin use was only associated with decreased microcalcification for the femoral-popliteal artery in multivariate analyses. Established CT-detectable calcium was not significantly associated with 18F-NaF uptake for 4 out of 5 arteries of interest. CONCLUSIONS: 18F-NaF PET/CT imaging quantifies vessel-specific active microcalcification in PAD that is increased in multiple lower extremity arteries by DM and CKD and decreased in the femoral-popliteal artery by statin use. 18F-NaF PET imaging is complementary to and largely independent of established CT-detectable arterial calcification. 18F-NaF PET/CT imaging may provide an approach for non-invasively quantifying vessel-specific responses to emerging anti-atherogenic therapies or CKD treatment in patients with PAD.
引用
- Chou TH, Rimmerman ET, Patel S, et al. Vessel-by-vessel analysis of lower extremity 18F-NaF PET/CT imaging quantifies diabetes- and chronic kidney disease-induced active microcalcification in patients with peripheral arterial disease. EJNMMI Res. 2023. PMID: 36648583. doi:10.1186/s13550-023-00951-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。